
FDA approved Novartis’ secukinumab (Cosentyx) 150 mg for adults with polymyalgia rheumatica who respond inadequately to corticosteroids or cannot tolerate a taper. In the Phase 3 REPLENISH trial, secukinumab doubled sustained remission rates.
Aesica adds roller compaction unit for dry granulation production.
The new roller compaction unit uses a continuous production step that enhances product uniformity and has been undertaken following a market demand for pharmaceutical formulation technologies that enable the formulation of APIs otherwise inhibited by the presence of water.
Source:






